Key result
Hepatocellular carcinoma linked to markedly elevated serum IL-6, AFP, and DCP compared to healthy controls.
Why the study?
Do serum levels of IL-6, AFP, and DCP differ between patients with hepatocellular carcinoma and healthy controls?
Case-Control (n=60)
Do serum levels of IL-6, AFP, and DCP differ between patients with hepatocellular carcinoma and healthy controls?
The combination of IL-6, DCP, and AFP may serve as promising tumor markers for improving the diagnosis of hepatocellular carcinoma.
Serum IL-6, AFP, and DCP elevations may aid HCC detection; leaves open routine adoption without validation in larger cohorts.
Background: Hepatocellular carcinoma (HCC) is one the most common primary malignancy of the liver and represents the third leading cause of cancer-related deaths worldwide. Incidence rates are highest in East Asia and Sub-Saharan Africa. A number of evidence suggests a possible role of interleukin-6 (IL-6), ?-Fetoprotein (AFP) and Des-?-carboxyprothrombin (DCP) in the pathogenesis of hepatocellular carcinoma (HCC). The high DCP may be related to increase tumour behaviour, such as the presence of vascular invasion and intrahepatic metastasis of HCC cells. Patients and methods: We studied IL-6, AFP and DCP in patients with HCC or in healthy controls. AFP was measured by chemiluminescent immunoassay; Serum IL-6 and DCP were measured by enzyme linked immunosorbent assay in 30 patients with primary hepatocellular carcinoma and 30 normal subjects.Results: IL-6, AFP and DCP were found high in the serum of patients initially diagnosed with HCC (18±9.8), (315.99±594.62) and (26.15±5.01) respectively compared with healthy subjects (4.29±2.10), (3.13±1.27) and (4.25±1.22). A significant positive correlation was found between mean levels of IL- 6 & AFP in HCC (P < 0.05), Combination of IL-6, AFP and DCP improved the sensitivity in diagnosing HCC or predicting future HCC development. Conclusions: IL-6, DCP along with AFP could be considered a promising tumor marker for HCC. DCP is a well recognized tumor marker for the screening and diagnosis of HCC. In particular, the diagnostic value of the test is significantly increased when combined with AFP.Bangladesh Journal of Medical Science Vol.15(2) 2016 p.230-233
No takes yet. Share an insight, caveat, or question.
Haque et al. (2016) conducted a case-control in Hepatocellular carcinoma (n=60). Primary hepatocellular carcinoma vs. Healthy subjects was evaluated on Serum levels of IL-6, AFP, and DCP. Patients with hepatocellular carcinoma had higher mean serum levels of IL-6 (18 vs 4.29), AFP (315.99 vs 3.13), and DCP (26.15 vs 4.25) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: